Biotron Limited

Biotron Limited (ASX: BIT) is a healthcare company that conducts clinical trials, research and commercialisation for anti-viral - HCV and HIV drugs that have been developed from biomedical projects researched at the John Curtin School of Medical Research. Lately, the group released the result for its lead drug, BIT225 HIV-1 Clinical Trial that outlined that BIT225 has a unique effect in patients, over and above viral suppression seen with current antiretroviral drugs. The outcomes have been in line with the concept on targeting and eradication of virus from macrophage reservoir cells by BIT225. This is of significance considering the impact in combination with current antiretroviral drugs and the immunological benefits in patients receiving antiretroviral drugs with 200 mg BIT225 against antiretroviral drugs plus placebo. Earlier, BIT225 was shown to target HIV-1 growing in macrophage cells leading to production of replication-incompetent virus i.e. non-infectious, dead virus. The data from the current BIT225-009 clinical trial also demonstrated about immune system’s recognition of dead virus that results in changes to the immune cells fighting the disease.

The key aspect to note is that the trial has been complex with no previous reference/ guidelines; and the group seems to be the first one to show the function of BIT225 in targeting and killing of virus residing in long-lived reservoir cells in humans.BIT now says that preliminary analysis of the safety data depicting tolerance around 200mg once daily dose has no severe adverse events or withdrawals; and the trial data is being analysed with detailed data representation scheduled to be made at scientific conferences and for potential commercial partners in late 2018 or early 2019.

Though the group has reported the above positive outcome that led to a stock price rise of 51.22% on October 01, 2018, the financial performance is yet to be improved as the group is yet to report significant revenue while the FY18 net loss has been down 48.5% $1,593,645.On the other hand, the group is focusing on setting defensible and strong patent portfolio with few grants in Australia in place while some international applications are under examination. Meanwhile, the group has raised capital of about $1.4 million after costs in FY18 and it also received R&D tax incentive rebate.

With 313.3% rise in stock price in the last one month, and earlier resistance at $ 0.068 and support at $0.050, the stock looks touch expensive at the current price of $ 0.100 (up by 61% on October 02, 2018). The group seems to be overbought for a while and can be watched while the stock has lately crossed its 200 days’ displaced moving average with a bullish trend. 

BIT Daily Chart (Source: Thomson Reuters)

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.